On September 9, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued advancement of Ampligen (rintatolimod) in pancreatic cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the CEO Corner, Equels discusses the significant challenges associated with pancreatic cancer, including its highly immunosuppressive – or "cold" – tumor microenvironment, which can prevent the immune system from mounting an effective response and has historically limited the effectiveness of many immunotherapy approaches.
Ampligen, AIM’s investigational TLR3 agonist, is designed to activate innate immunity and help reshape the tumor microenvironment, potentially making tumors more responsive to checkpoint inhibition. Based on existing data, AIM believes Ampligen may have a broad-spectrum synergistic effect with both PD-1 checkpoint inhibitors such as pembrolizumab, and PD-L1 checkpoint inhibitors such as durvalumab.
This scientific rationale is being evaluated through the Company’s ongoing Phase 2 DURIPANC study, which is assessing Ampligen in combination with AstraZeneca’s durvalumab as maintenance therapy following standard-of-care treatment in patients with pancreatic cancer. AIM believes the study has the potential to provide important insights into patient selection, biomarker identification and the characteristics of patients who may derive the greatest clinical benefit, helping inform the design of a potential future pivotal development program.
"Pancreatic cancer remains one of oncology’s most difficult diseases, in large part because its immunosuppressive tumor microenvironment creates significant barriers to effective immune responses," said Equels. "Our strategy with Ampligen is designed to address that underlying biology by activating innate immunity and potentially making these tumors more responsive to checkpoint inhibition. As we continue to advance DURIPANC, biomarker research and our broader clinical development strategy, we believe the data generated can further strengthen our understanding of Ampligen’s mechanism of action and its potential role in addressing this significant unmet medical need."
Beyond DURIPANC, AIM continues to build a broader body of scientific and clinical evidence supporting Ampligen through collaborations with leading institutions, ongoing biomarker research, expansion of its intellectual property portfolio and continued regulatory engagement.
Looking ahead in DURIPANC, the Company expects primary endpoint analyses, continued biomarker evaluations and overall survival follow-up. It also plans future regulatory interactions to provide additional opportunities to evaluate Ampligen’s potential and refine AIM’s long-term pancreatic cancer development strategy.
The latest CEO Corner segment is now available on the Company’s website here.
(Press release, AIM ImmunoTech, SEP 9, 2026, View Source [SID1234670665])